Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)
Journal of the American Academy of Dermatology · 2026-09 · 95 (3) · 882-884
DOI: 10.1016/j.jaad.2026.05.080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Mao-Ling Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Immunodermatology, Ministry of Educatio…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Liaoning Provincial Natural Science Foundation, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission, National Joint Engineering Research…
- Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China; Key Laboratory of Precision Prevention and Treatment for Obesity and Metabolic Diseases, China Medical Universi…
Förderung
- National Key Research and Development Program of China
- Liaoning Provincial Natural Science Foundation
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Sun, M. L., Wang, S. W., Gao, Y. Q., Chen, Z. Y., Liu, X. D., Gao, X. H., & Guo, Y. X. (2026). Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS). Journal of the American Academy of Dermatology, 95(3), 882-884. https://doi.org/10.1016/j.jaad.2026.05.080
Vancouver
Sun ML, Wang SW, Gao YQ, Chen ZY, Liu XD, Gao XH, et al. Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS). Journal of the American Academy of Dermatology. 2026;95(3):882-884. doi:10.1016/j.jaad.2026.05.080
BibTeX
@article{Sun2026,
author = {Sun, Mao-Ling and Wang, Si-Wen and Gao, Yun-Qiu and Chen, Zhi-Yuan and Liu, Xin-De and Gao, Xing-Hua and Guo, Ya-Xin},
title = {Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {3},
pages = {882--884},
doi = {10.1016/j.jaad.2026.05.080}
}
EUVIMED